Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...

The National Institute for Health and Care Excellence (NICE) has rejected the Alzheimer’s drug donanemab because the ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...